Literature DB >> 20140811

A year of successful cancer vaccines points to a path forward.

Michael A Morse1, Michael Whelan.   

Abstract

Results from recent clinical trials of the therapeutic vaccines sipuleucel-T (Dendreon Corp), PROSTVAC-VF-TRICOM (National Cancer Institute/BN ImmunoTherapeutics Inc) and BiovaxID (Biovest International Inc) are highlighted. These data support the further development of such vaccines, and provide guidance for the development of improved agents and protocols for the use of therapeutic vaccination to treat cancer.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20140811

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  13 in total

1.  Oncoantigens for an immune prevention of cancer.

Authors:  Elisabetta Bolli; Elena Quaglino; Maddalena Arigoni; Pier-Luigi Lollini; Raffaele Calogero; Guido Forni; Federica Cavallo
Journal:  Am J Cancer Res       Date:  2010-12-20       Impact factor: 6.166

2.  Active-specific immunotherapy for non-small cell lung cancer.

Authors:  Hauke Winter; Natasja K van den Engel; Margareta Rusan; Nina Schupp; Christian H Poehlein; Hong-Ming Hu; Rudolf A Hatz; Walter J Urba; Karl-Walter Jauch; Bernard A Fox; Dominik Rüttinger
Journal:  J Thorac Dis       Date:  2011-06       Impact factor: 2.895

3.  A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors.

Authors:  Jeffrey S Weber; Nicholas J Vogelzang; Marc S Ernstoff; Oscar B Goodman; Lee D Cranmer; John L Marshall; Sabrina Miles; Dar Rosario; David C Diamond; Zhiyong Qiu; Mihail Obrocea; Adrian Bot
Journal:  J Immunother       Date:  2011-09       Impact factor: 4.456

Review 4.  Molecular genetics of prostate cancer: new prospects for old challenges.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Genes Dev       Date:  2010-09-15       Impact factor: 11.361

5.  Programmed cell death-1 (PD-1) at the heart of heterologous prime-boost vaccines and regulation of CD8+ T cell immunity.

Authors:  Adrian Bot; Zhiyong Qiu; Raymond Wong; Mihail Obrocea; Kent A Smith
Journal:  J Transl Med       Date:  2010-12-14       Impact factor: 5.531

6.  Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.

Authors:  Vani Lakshminarayanan; Pamela Thompson; Margreet A Wolfert; Therese Buskas; Judy M Bradley; Latha B Pathangey; Cathy S Madsen; Peter A Cohen; Sandra J Gendler; Geert-Jan Boons
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-14       Impact factor: 11.205

7.  Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.

Authors:  Abu-Baker M Abdel-Aal; Vani Lakshminarayanan; Pamela Thompson; Nitin Supekar; Judy M Bradley; Margreet A Wolfert; Peter A Cohen; Sandra J Gendler; Geert-Jan Boons
Journal:  Chembiochem       Date:  2014-05-30       Impact factor: 3.164

8.  ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway.

Authors:  Nicholas S Wilson; Becky Yang; Adriana Baz Morelli; Sandra Koernig; Annie Yang; Stefanie Loeser; Denise Airey; Larissa Provan; Phil Hass; Hal Braley; Suzana Couto; Debbie Drane; Jeff Boyle; Gabrielle T Belz; Avi Ashkenazi; Eugene Maraskovsky
Journal:  Immunol Cell Biol       Date:  2011-09-06       Impact factor: 5.126

9.  Using lymph node swelling as a potential biomarker for successful vaccination.

Authors:  Kimberly D Brewer; Drew R DeBay; Iulia Dude; Christa Davis; Kerry Lake; Cathryn Parsons; Rajkannan Rajagopalan; Genevieve Weir; Marianne M Stanford; Marc Mansour; Chris V Bowen
Journal:  Oncotarget       Date:  2016-06-14

10.  Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines.

Authors:  Drew R DeBay; Kimberly D Brewer; Sarah A LeBlanc; Genevieve M Weir; Marianne M Stanford; Marc Mansour; Chris V Bowen
Journal:  Mol Ther Methods Clin Dev       Date:  2015-12-16       Impact factor: 6.698
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.